Mergers and acquisitions (M&As) in the biopharmaceutical industry surged 101% in total deal value in the first quarter (Q1) ...

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Recursion Pharmaceuticals has narrowed its drug development pipeline as it seeks to reduce costs and reprioritise resources.

Bristol Myers Squibb (BMS) plans to invest $40bn in the US over the next five years to bolster its research and manufacturing ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), once focused on treating diabetes and obesity, are now emerging as ...

The options are for the freeze-dried version of Bavarian Nordic’s Jynneos, a formulation that allows easier stockpiling.

Teva and Alvotech have announced receipt of the US FDA approval to Selarsdi injection for use as an interchangeable with ...

Research and development (R&D) investment in the Swiss biotech sector grew in 2024, despite ongoing global funding struggles.